Nuvation Competitors
| NUVB Stock | USD 5.72 0.08 1.42% |
Nuvation Bio vs Ocular Therapeutix Correlation
Poor diversification
The correlation between Nuvation Bio and OCUL is 0.62 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Nuvation Bio and OCUL in the same portfolio, assuming nothing else is changed.
Moving against Nuvation Stock
| 0.55 | KRRO | Frequency Therapeutics | PairCorr |
| 0.47 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.4 | EVGN | Evogene | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nuvation Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nuvation Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nuvation Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nuvation and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nuvation Bio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Nuvation Stock performing well and Nuvation Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nuvation Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GPCR | 5.12 | 1.93 | 0.42 | (1.82) | 3.40 | 8.23 | 112.39 | |||
| EWTX | 4.13 | 0.92 | 0.20 | 0.87 | 4.24 | 12.91 | 38.85 | |||
| JANX | 3.37 | (0.80) | 0.00 | (0.44) | 0.00 | 7.88 | 63.52 | |||
| QURE | 4.07 | (0.28) | 0.00 | 1.81 | 0.00 | 9.37 | 28.69 | |||
| VERA | 3.67 | 0.80 | 0.30 | 0.47 | 2.57 | 10.77 | 23.44 | |||
| CLDX | 2.47 | 0.02 | 0.00 | 0.05 | 0.00 | 6.44 | 14.68 | |||
| VRDN | 1.94 | 0.41 | 0.18 | 1.31 | 1.62 | 5.57 | 17.41 | |||
| ABCL | 3.53 | (0.62) | 0.00 | 0.88 | 0.00 | 6.33 | 28.69 | |||
| AUPH | 1.67 | 0.14 | 0.03 | 0.85 | 2.02 | 4.73 | 14.64 | |||
| OCUL | 2.97 | (0.12) | 0.00 | 30.92 | 0.00 | 6.04 | 36.20 |
Cross Equities Net Income Analysis
Compare Nuvation Bio and related stocks such as Structure Therapeutics, Edgewise Therapeutics, and Janux Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (40 M) | (51.3 M) | (89.6 M) | (122.5 M) | (110.3 M) | (104.8 M) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| QURE | (22.4 M) | (22.4 M) | (19.5 M) | (37 M) | (45 M) | (78.1 M) | (73.4 M) | (80.4 M) | (83.3 M) | (124.2 M) | (125 M) | 329.6 M | (126.8 M) | (308.5 M) | (239.6 M) | (215.6 M) | (204.8 M) |
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
| VRDN | (7.2 M) | (7.2 M) | (7.2 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| AUPH | (2.2 M) | (2.4 M) | (9.7 M) | (2.5 M) | (16.6 M) | (18.6 M) | (23.3 M) | (70.8 M) | (64.1 M) | (88.4 M) | (102.7 M) | (181 M) | (108.2 M) | (78 M) | 5.8 M | 5.2 M | 5.4 M |
| OCUL | (14.1 M) | (14.1 M) | (14.1 M) | (13.3 M) | (28.6 M) | (39.7 M) | (44.7 M) | (63.4 M) | (57.7 M) | (86.4 M) | (155.6 M) | (6.6 M) | (71 M) | (80.7 M) | (193.5 M) | (265.9 M) | (252.6 M) |
Nuvation Bio and related stocks such as Structure Therapeutics, Edgewise Therapeutics, and Janux Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Nuvation Bio financial statement analysis. It represents the amount of money remaining after all of Nuvation Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Nuvation Bio Competitive Analysis
The better you understand Nuvation Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nuvation Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nuvation Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Nuvation Bio Competition Performance Charts
Five steps to successful analysis of Nuvation Bio Competition
Nuvation Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nuvation Bio in relation to its competition. Nuvation Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Nuvation Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nuvation Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nuvation Bio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Nuvation Bio position
In addition to having Nuvation Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Services Thematic Idea Now
Communication Services
Companies that provide networking, telecom, and long distance services. The Communication Services theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Nuvation Bio Correlation with its peers. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. Anticipated expansion of Nuvation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Nuvation Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 17.047 | Return On Assets | Return On Equity |
Understanding Nuvation Bio requires distinguishing between market price and book value, where the latter reflects Nuvation's accounting equity. The concept of intrinsic value - what Nuvation Bio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Nuvation Bio's price substantially above or below its fundamental value.
It's important to distinguish between Nuvation Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nuvation Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nuvation Bio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.